An active safety surveillance study for the nasal live-attenuated influenza vaccine (LAIV) Fluenz Tetra during the 2014/2015 influenza season

Trial Profile

An active safety surveillance study for the nasal live-attenuated influenza vaccine (LAIV) Fluenz Tetra during the 2014/2015 influenza season

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs MEDI 3250 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 20 Dec 2014 Planned End Date changed from 31 Oct 2014 to 2 Jan 2015 as reported by United Kingdom Clinical Research Network.
    • 10 Dec 2014 Accrual to date is 166% according to United Kingdom Clinical Research Network record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top